Abstract 4548
Background
Precision medicine is associated with favorable outcomes in selected patients. We initiated IMPACT 2, a randomized study to compare PFS in patients with metastatic cancer treated on the basis of tumor genomic profiling results vs. those whose treatment was not selected based on genomic analysis. Herein, we assessed the association between patient characteristics and overall survival (OS).
Methods
Patients with advanced, metastatic cancer underwent tumor biopsy and genomic profiling (Foundation One). Variants were filtered to eliminate germline mutations (annotation, ANNOVAR) and artifacts. Patients were presented at tumor board and were randomized if they met criteria for clinical trials. OS was measured from enrollment on study until last follow-up or death from any cause.
Results
From 5/2014 to 4/2017, 320 of 391 enrolled patients completed tumor profiling. Baseline characteristics (n = 320) were as follows: men, 47%; median age, 63 yrs (range, 25-83); performance status 1, 88%; median no. of prior therapies, 3 (range, 0-14); liver metastases, 40%; albumin < 3.5 g/L, 12%; LDH > 618 IU/L, 29%; platelet count > or < the normal limits, 15%. Most common tumor types were head and neck, 19%; gastrointestinal, 16%; and lung, 11%. Most frequently mutated genes: TP53, 42%; KRAS,16%; PIK3CA,12%; and CDKN2A, 11%. Of 320 patients, 69 (22%) were randomized; of the remaining 251 patients, 153 (61%) received other treatment (investigational or standard). Results of multivariate analyses for OS are displayed below.Table:
449PD
Multivariate analysis, OS | |||
---|---|---|---|
Risk Factor | HR | 95% CI | P |
Age ≥ 60 yrs | 1.02 | 1.00-1.03 | .009 |
Liver metastases | 1.43 | 1.07-1.91 | .02 |
LDH > 618 IU/L | 2.19 | 1.61-2.97 | < .0001 |
Albumin < 3.5 g/dL | 1.90 | 1.26-2.87 | .002 |
KRAS mutated | 2.27 | 1.57-3.28 | < .0001 |
TP53 mutated | 1.38 | 1.04-1.84 | .03 |
Conclusions
In patients with metastatic cancer, age < 60 yrs, absence of liver metastases, normal albumin and LDH levels, and absence of KRAS or TP53 mutations were independent factors predicting longer OS. We demonstrated the feasibility of molecular profiling using newly obtained tumor biopsies and treating patients prospectively. The study is ongoing. Outcomes for randomized patients are awaited upon completion of the study.
Clinical trial identification
www.clinicaltrials.gov NCT02152254, First posted June 2, 2014.
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Foundation Medicine.
Disclosure
A.M. Tsimberidou: Research grant / Funding (institution): IMMATICS; Research grant / Funding (institution): Tempus; Research grant / Funding (institution): Parker Institute for Cancer Immunotherapy; Research grant / Funding (institution): EMD Serono; Research grant / Funding (institution): Baxalta; Research grant / Funding (institution): Foundation Medicine; Research grant / Funding (institution): Boston Biomedical; Research grant / Funding (institution): Placon Therapeutics; Research grant / Funding (institution): Karus Therapeutics; Research grant / Funding (institution): Tvardi; Research grant / Funding (institution): OBI Pharma; Advisory / Consultancy: Roche, Europe; Advisory / Consultancy: Covance; Advisory / Consultancy: Genentech. D.S. Hong: Research grant / Funding (self): Adaptimmune; Research grant / Funding (institution): Abbvie; Research grant / Funding (institution): Amgen; Research grant / Funding (institution): AstraZeneca; Research grant / Funding (self): Bayer; Research grant / Funding (institution): BMS; Research grant / Funding (institution): Daichi-Sanko; Research grant / Funding (institution): Eisai; Research grant / Funding (institution): Genentech; Research grant / Funding (institution): Genmab; Research grant / Funding (institution): Ignyta; Research grant / Funding (institution): Infinity; Research grant / Funding (institution): Kite; Research grant / Funding (institution): Lilly; Research grant / Funding (institution): LOXO; Research grant / Funding (institution): Mirati; Research grant / Funding (institution): Merck; Research grant / Funding (institution): Medimmune; Research grant / Funding (institution): Molecular Template; Research grant / Funding (institution): Novartis. All other authors have declared no conflicts of interest.
Resources from the same session
5576 - Genomic characteristics and predicted ancestry of NTRK1/2/3 and ROS1 fusion-positive tumors from >165,000 pan-solid tumors
Presenter: Timothy R Wilson
Session: Poster Discussion – Developmental therapeutics
Resources:
Abstract
4536 - Safety and preliminary clinical activity of repotrectinib in patients with advanced ROS1/TRK fusion-positive solid tumors (TRIDENT-1 study)
Presenter: Alexander Drilon
Session: Poster Discussion – Developmental therapeutics
Resources:
Abstract
5684 - Durability of response with larotrectinib in adult and pediatric patients with TRK fusion cancer
Presenter: David Hyman
Session: Poster Discussion – Developmental therapeutics
Resources:
Abstract
2937 - Phase 1 Study of AMG 510, a Novel Molecule Targeting KRAS G12C Mutant Solid Tumors
Presenter: Ramaswamy Govindan
Session: Poster Discussion – Developmental therapeutics
Resources:
Abstract
4748 - Phase 1/2 study of combined BCL-XL and MEK inhibition with navitoclax (N) and trametinib (T) in KRAS or NRAS mutant advanced solid tumors
Presenter: Ryan Corcoran
Session: Poster Discussion – Developmental therapeutics
Resources:
Abstract
4556 - Genomic Profiling of Three Pathways through Molecular Profiling-based Assignment of Cancer Therapy (NCI- MPACT)
Presenter: Alice Chen
Session: Poster Discussion – Developmental therapeutics
Resources:
Abstract
1915 - A Phase I study of ATR inhibitor, AZD6738, as monotherapy in advanced solid tumours (PATRIOT Part A, B)
Presenter: Magnus Dillon
Session: Poster Discussion – Developmental therapeutics
Resources:
Abstract
4517 - Updated results of the PARP1/2 inhibitor pamiparib in combination with low-dose (ld) temozolomide (TMZ) in patients (pts) with locally advanced or metastatic solid tumors
Presenter: Agostina Stradella
Session: Poster Discussion – Developmental therapeutics
Resources:
Abstract
2588 - Safety, antitumor activity, and pharmacokinetics (PK) of pamiparib (BGB-290), a PARP1/2 inhibitor, in patients (pts) with advanced solid tumors: updated phase 1 dose-escalation/expansion results
Presenter: Mark Voskoboynik
Session: Poster Discussion – Developmental therapeutics
Resources:
Abstract
3575 - Safety, Anti-Tumor Activity, and Biomarker Results of the HER2-Targeted Bispecific Antibody ZW25 in HER2-Expressing Solid Tumors
Presenter: Funda Meric-Bernstam
Session: Poster Discussion – Developmental therapeutics
Resources:
Abstract